Understanding Intermediate-Risk Breast Cancer Outcomes

Managing hormone receptor (HR)-positive/HER2-negative early breast cancer (EBC) requires precise risk stratification to determine the best adjuvant strategy. A recent retrospective analysis by Servitja S et al. provides essential insights into intermediate-risk breast cancer outcomes. This study evaluates long-term relapse risks, which are critical for oncologists when prescribing modern adjuvant therapies like CDK4/6 inhibitors. Given that breast cancer remains a leading health challenge in India, these findings offer a valuable framework for clinical decision-making.

The researchers conducted a massive retrospective analysis involving 8,825 patients. These individuals were recruited from five GEICAM adjuvant trials and the El Álamo IV registry. To facilitate the study, the team categorized patients into three distinct risk cohorts. Cohort 1 represented high-risk stage III cases, while Cohort 3 included low-risk stage I patients. Specifically, Cohort 2 focused on intermediate-risk patients, including those with T0-2N1 or T3N0 tumors. Additionally, this group included T2N0 patients with high histological grades or specific Ki-67 levels.

Clinical Implications of the GEICAM Analysis

Furthermore, the data highlight the evolving standard of care for patients with significant relapse risks. Standard endocrine therapy (ET) often fails to prevent late recurrences in intermediate-risk populations. Consequently, clinical trials like NATALEE have explored more aggressive interventions. The NATALEE trial demonstrated that adding three years of ribociclib to ET improves 4-year invasive Disease-Free Survival (iDFS) by 4.9%. This finding aligns with the GEICAM study’s emphasis on identifying patients who truly require intensified adjuvant treatment.

Moreover, the GEICAM analysis underscores the importance of real-world data in validating trial results. While the NATALEE trial provides a benchmark, retrospective data from nearly 9,000 patients offer a broader perspective on long-term survival. For Indian clinicians, these insights are particularly relevant because many patients present with intermediate-risk features. Therefore, understanding the natural history of relapse in this subgroup helps in personalizing the use of expensive new drugs. Ultimately, the study suggests that careful risk grouping remains the cornerstone of effective breast cancer management.

Frequently Asked Questions

How was the intermediate-risk group defined in this analysis?

The intermediate-risk group (Cohort 2) included patients with T0-2N1, T3N0, or T2N0 tumors. These patients also had to exhibit either a histological grade 3 or a grade 2 with a Ki-67 index of 20% or higher.

What impact did the NATALEE trial have on this patient population?

The NATALEE trial showed that adding ribociclib to endocrine therapy for three years significantly improved the 4-year invasive Disease-Free Survival (iDFS) by 4.9% compared to endocrine therapy alone in high- and intermediate-risk patients.

Why is long-term risk of relapse data important for clinical decisions?

Long-term data allow oncologists to weigh the benefits of additional adjuvant therapies against potential toxicities. This is vital when deciding on the prescription of newer, long-term treatments like CDK4/6 inhibitors.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional physician-patient relationship. Always seek the advice of a qualified healthcare provider for any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Servitja S et al. Outcomes of Hormone receptor-positive/HER2-negative early breast cancer patients by risk of recurrence groups focusing on the intermediate-risk group: Retrospective analysis from GEICAM studies. Breast Cancer Res. 2026 May 25. doi: 10.1186/s13058-026-02300-0. PMID: 42185928.

2. Fasching PA et al. Ribociclib plus nonsteroidal aromatase inhibitor in patients with HR+/HER2- early breast cancer: 4-year outcomes from the NATALEE randomized clinical trial. JAMA Oncol. 2025;11(1):12-21.

3. Indian Council of Medical Research (ICMR). Consensus Document for Management of Breast Cancer. New Delhi: ICMR; 2024.